Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma ; volume:22 ; number:1 ; day:31 ; month:12 ; year:2024 ; pages:1-23 ; date:12.2024
Cell communication and signaling ; 22, Heft 1 (31.12.2024), 1-23, 12.2024

Creator: Sævarsson, Teitur
Lomana, Adrián López García de
Sánchez, Ólafur
Esch, Veerle van
Ragnarsson, Gunnar Bjarni
Brynjólfsson, Siggeir Fannar
Steingrímsson, Eiríkur
Einarsdóttir, Berglind Ósk

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12964-024-01963-6

URN: urn:nbn:de:101:1-2503072130269.912282840996

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sævarsson, Teitur
Lomana, Adrián López García de
Sánchez, Ólafur
Esch, Veerle van
Ragnarsson, Gunnar Bjarni
Brynjólfsson, Siggeir Fannar
Steingrímsson, Eiríkur
Einarsdóttir, Berglind Ósk
SpringerLink (Online service)

Other Objects (12)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma

An IFNγ/CXCL2 regulatory pathway determines lesion localization during EAE

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Hochschulschrift

PD-L1 Expression in malignen Melanomen der Vulva

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma

An IFNγ/CXCL2 regulatory pathway determines lesion localization during EAE

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Hochschulschrift

PD-L1 Expression in malignen Melanomen der Vulva

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma

An IFNγ/CXCL2 regulatory pathway determines lesion localization during EAE

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Hochschulschrift

PD-L1 Expression in malignen Melanomen der Vulva

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma

An IFNγ/CXCL2 regulatory pathway determines lesion localization during EAE

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 Expression in malignen Melanomen der Vulva

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma

An IFNγ/CXCL2 regulatory pathway determines lesion localization during EAE

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 Expression in malignen Melanomen der Vulva

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma

An IFNγ/CXCL2 regulatory pathway determines lesion localization during EAE

PD-L1 Expression als Prognosemarker beim Endometriumkarzinom

Factors correlating the expression of PD-L1

Optimized PD-L1 scoring of gastric cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 Expression in malignen Melanomen der Vulva

Related objects

Reset password